J&J and Gen­mab tout first-line in­jectable Darza­lex for mul­ti­ple myelo­ma: #ASH23

SAN DIEGO — J&J and Gen­mab fleshed out their case Tues­day morn­ing to move their sub­cu­ta­neous ver­sion of the can­cer drug Darza­lex in­to ear­li­er lines of treat­ment.

The da­ta for Darza­lex Faspro, the brand name for sub­cu­ta­neous Darza­lex, came from the Phase III PERSEUS tri­al that en­rolled 709 pa­tients. Those tak­ing the drug plus a stan­dard chemo reg­i­men were 58% less like­ly to see their can­cers progress com­pared to the chemo reg­i­men on its own. Physi­cians ad­min­is­tered Darza­lex Faspro in both an in­duc­tion phase and a main­te­nance phase.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER